BGB Group Acquires Hayden to Master Biopharma Market Access

NEW YORK, NY – January 07, 2026 – BGB Group, a prominent commercial solutions company for the life sciences industry, announced today its acquisition of Hayden Consulting Group, a highly regarded consultancy specializing in market access and patient services. The move significantly strengthens BGB’s strategic advisory capabilities, creating a comprehensive, integrated offering designed to guide biopharmaceutical companies through an increasingly difficult commercial landscape. Financial terms of the deal were not disclosed.

The acquisition unites Hayden’s deep expertise in navigating complex payer, reimbursement, and affordability obstacles with BGB's established strengths in strategic advisory, medical communications, and advertising. Hayden will now operate as part of BGB’s Strategic Advisory practice, which is led by Hilary Gentile, Chief of Commercial Strategy and Innovation. Hayden co-founders Jamie Sidore and David MacDougall will continue to lead their group within the new structure.

A Strategic Response to a Complex Market

The acquisition arrives at a critical juncture for the biopharmaceutical industry, which is facing unprecedented pressure on pricing and market access. Companies launching new therapies must contend with escalating payer scrutiny, a growing demand for real-world evidence of value, and a complex web of regulatory shifts. Securing favorable formulary placement and ensuring patient affordability have become paramount challenges that can determine a product's commercial success or failure.

“In an industry where regulatory shifts and economic pressures can sideline promising therapies, this acquisition is a game-changer for our clients,” said David Coman, Chief Executive Officer of BGB Group, in the official announcement. He emphasized that Hayden’s expertise “naturally aligns with BGB’s capabilities and elevates BGB’s ability to guide the full commercial journey.”

Hayden Consulting Group, founded in 2019, built its reputation by focusing exclusively on these critical hurdles. The firm is known for its data-driven approach to developing strategies that integrate market access considerations into the core of a brand's commercialization plan, rather than treating them as a late-stage afterthought. This philosophy is crucial in an environment where early planning for payer negotiations and patient support programs is essential.

“Our clients demand market access strategies that are seamlessly embedded as part of their commercialization plan and not as an afterthought,” noted Dave MacDougall, Managing Director and Co-Founder of Hayden. “The combined company scales that vision, delivering value that transforms challenges into opportunities of growth for our customers.”

Building the 'One-Stop Shop' for Biopharma

This acquisition is a definitive step in BGB Group’s strategy to become a singular, connected partner for its clients, capable of managing the entire brand lifecycle. By folding Hayden’s specialized services into its portfolio, BGB can now offer a seamless suite of solutions that extends from early-stage commercial due diligence and new product planning to go-to-market strategy, launch execution, and post-launch communications.

This integrated model aims to eliminate the fragmentation that often occurs when biopharma companies engage multiple, disparate agencies and consultancies for strategy, market access, medical communications, and advertising. The goal is to provide a more efficient, cohesive, and powerful pathway to market, ensuring that all aspects of a commercial plan are aligned from the outset.

Jamie Sidore, Managing Director and Co-Founder of Hayden, highlighted this benefit. “By joining forces with BGB Group, Hayden can offer clients integrated solutions that span New Product Planning to Commercialization and Launch Execution - from our existing Access, Affordability and Patient Services capabilities - all the way through to the execution of Communications and Advertising,” he stated. “The combined businesses truly represent industry-leading capabilities under one roof.”

Consolidation and Growth Fueled by Private Equity

BGB Group's acquisition of Hayden is the latest move in a deliberate expansion strategy that has accelerated since the company partnered with global alternative asset management firm TPG in 2021. The significant investment from TPG, which valued BGB at approximately $760 million at the time, provided the capital to pursue strategic “bolt-on” acquisitions and capability enhancements.

This pattern of growth is not new for BGB. In September 2023, the company acquired Kx Advisors, a healthcare strategy consultancy that bolstered its expertise in areas like pipeline prioritization, market expansion, and pricing analysis. This was followed by a strategic partnership with agile creative agency Scrum50 in February 2024, aimed at bringing consumer marketing science to its healthcare clients.

The addition of Hayden Consulting Group fits squarely within this strategy, adding a critical and highly specialized market access component. This trend reflects a broader consolidation within the healthcare consulting and agency sectors, where private equity firms are helping to scale service providers to create more comprehensive and competitive offerings. These larger, integrated entities are better positioned to compete with established giants in the life sciences consulting space, such as IQVIA and ZS Associates, where Hayden’s own leadership has prior experience.

The Path to Integration and a Shifting Landscape

For biopharmaceutical clients, the promise of this merger lies in the potential for greater synergy and streamlined execution. An integrated partner can ensure that the value proposition articulated to clinicians through medical communications is consistent with the evidence presented to payers for reimbursement, and that patient support programs are designed with a deep understanding of the access barriers identified during strategic planning. This holistic approach is designed to maximize a therapy’s commercial potential and, ultimately, its impact on patient lives.

The challenge for BGB Group will be to successfully integrate Hayden’s distinct culture and specialized focus without diluting its expertise. Maintaining the entrepreneurial spirit and deep analytical rigor that made Hayden a sought-after partner will be critical to realizing the full value of the acquisition. Effective management will be needed to break down potential internal silos and foster true cross-functional collaboration between the strategic, creative, and market access teams.

This acquisition not only enhances BGB’s competitive posture but also signals a significant evolution in the biopharma support ecosystem. As the path to market becomes more fraught with complexity, the demand for unified, end-to-end commercialization partners is growing, shifting the landscape away from fragmented vendor relationships toward more holistic strategic alliances.